

Claims:

1. An antibody or antigen binding fragment, optionally isolated, which is capable of binding to IL-11, wherein the antibody or antigen binding fragment comprises:

(i) a light chain variable region sequence comprising the following CDRs:

LC-CDR1: SSDVGGYNY (SEQ ID NO:107)

LC-CDR2: DVN (SEQ ID NO:291)

LC-CDR3: CSYAGRYTWM (SEQ ID NO:336), or a variant comprising 1 amino acid substitution in the sequence CSYAGRYTWM (SEQ ID NO:336), and

(ii) a heavy chain variable region sequence comprising the following CDRs:

HC-CDR1: GFTFSSYG (SEQ ID NO:186)

HC-CDR2: ISYDGSNK (SEQ ID NO:184)

HC-CDR3: AKIGATDPLDY (SEQ ID NO:187);

and wherein the antibody or antigen binding fragment inhibits IL-11-mediated signalling.

2. The antibody or antigen binding fragment according to claim 1, wherein:

the light chain variable region sequence has at least 80% sequence identity to the light chain variable region sequence of SEQ ID NO:335, and

the heavy chain variable region sequence has at least 80% sequence identity to the heavy chain variable region sequence of SEQ ID NO:370.

3. The antibody or antigen binding fragment according to claim 1 or claim 2, wherein:

the light chain variable region sequence is a variant of the light chain variable region sequence of SEQ ID NO:335 comprising 1 amino acid substitution in the sequence of SEQ ID NO:335, and

the heavy chain variable region sequence is the heavy chain variable region sequence of SEQ ID NO:370.

4. The antibody or antigen binding fragment according to any one of claims 1 to 3, conjugated to a drug moiety or a detectable moiety.

5. An isolated nucleic acid encoding the antibody or antigen binding fragment according to any one of claims 1 to 4.

6. A vector comprising the nucleic acid of claim 5.

7. A host cell comprising the vector of claim 6.

8. A method for making an antibody or antigen binding fragment according to any one of claims 1 to 4, comprising culturing the host cell of claim 7 under conditions suitable for the expression of the antibody or antigen binding fragment, and recovering the antibody or antigen binding fragment.

9. Use of an antibody or antigen binding fragment according to any one of claims 1 to 4, in the manufacture of a medicament for use in the treatment or prevention of fibrosis, or a disease/disorder characterised by fibrosis selected from: pulmonary fibrosis, atrial fibrillation, ventricular fibrillation, hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), non-alcoholic steatohepatitis (NASH), cirrhosis, chronic kidney disease, scleroderma, systemic sclerosis, keloid, cystic fibrosis, Chron's disease, post-surgical fibrosis, retinal fibrosis and retinal fibrosis associated with wet age-related macular degeneration (AMD).

10. The use according to claim 9, wherein the fibrosis is fibrosis of an organ of the gastrointestinal system, respiratory system, cardiovascular system, nervous system, urinary system or musculoskeletal system, or the skin.

11. The use according to claim 9, wherein the fibrosis is fibrosis of one or more organs selected from the lung, liver, kidney, heart, blood vessels, eye, skin, pancreas, spleen, bowel, large intestine, small intestine, brain and bone marrow.

12. Use of an antibody or antigen binding fragment according to any one of claims 1 to 4, in the manufacture of a medicament for use in the treatment or prevention of a disease/disorder characterised by inflammation selected from: allergic inflammation, allergic asthma, bronchial inflammation, atopic dermatitis, allergic rhinitis, an ocular allergic disease, an autoimmune disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, chronic active hepatitis, type 1 diabetes mellitus, celiac disease, Grave's disease, uveitis, pemphigus, psoriasis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, anaemia and autoimmune thyroiditis.

13. Use of an antibody or antigen binding fragment according to any one of claims 1 to 4, in the manufacture of a medicament for use in the treatment or prevention of a cancer selected from: an epithelial cell cancer, breast cancer, gastrointestinal cancer, esophageal cancer, stomach cancer, pancreatic cancer, liver cancer, hepatocellular cancer, gallbladder cancer, colorectal cancer, colonic cancer, anal cancer, gastrointestinal carcinoid tumor, lung cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and lung adenocarcinoma.

14. A method comprising contacting a sample containing, or suspected to contain, IL-11 with an antibody or antigen binding fragment according to any one of claims 1 to 4 and detecting the formation of a complex of the antibody or antigen binding fragment with IL-11.

15. A method of diagnosing a disease or condition in a subject, the method comprising contacting, *in vitro*, a sample from the subject with an antibody or antigen binding fragment according to any one of claims 1 to 4 and detecting the formation of a complex of the antibody or antigen binding fragment with IL-11.

16. A method of selecting or stratifying a subject for treatment with an IL-11-targeted agent, the method comprising contacting, *in vitro*, a sample from the subject with the antibody or antigen binding fragment

according to any one of claims 1 to 4 and detecting the formation of a complex of the antibody or antigen binding fragment with IL-11.

5 17. Use of an antibody or antigen binding fragment according to any one of claims 1 to 4 for the detection of IL-11 *in vitro*.

18. Use of an antibody or antigen binding fragment according to any one of claims 1 to 4 as an *in vitro* diagnostic or prognostic agent.

10